The Company Strategy
Redfund Capital is the first medical cannabis incubator and accelerator financing medical cannabis, CBD and hemp companies through a debt facility to bridge finance and help revenue producing medical cannabis related companies build their valuation, and grow their company without diluting their equity prematurely.
The core component of Redfund’s business strategy is to establish the foundation for a loan portfolio that not only generates revenues with monthly interest income from our loans to cover all the Company’s general and administrative expenses related to the day-to-day operations of the merchant bank, but to simultaneously grow our shareholder value by converting whole or part of our loans and warrants into equity in our portfolio clients as they build their valuations entering the public markets or become high priced targets of larger entities.
Redfund is pleased to report it has already extended funds for 5 signed promissory notes and has over 11 companies in the pipeline at various due diligence stages. In accordance with notes signed with our clients not all terms details may be disclosed.
The Company loan portfolio consists of the following companies as of November 5th 2018:
Biolog Inc. (“BI”) a cannabis infusion technology company, based in Silicon Valley, California, that has developed a patented system to infuse food and beverages with cannabis, powered by Lexaria Bioscience Corp‘s DehydraTECHTM technology. Refund equity upside: with warrant exercise and note convertibility to acquire 10% of BI.
Biominerales Pharma Colombia (“BP”) the trailblazer in Colombia medical cannabis, that has the trifecta of licenses in Colombia allowing the company to grow, process and export CBD oil beyond South America to the global marketplace and is harvesting crop now. Redfund equity upside: with warrant exercise and note convertibility to acquire close to 30% equity in BP.
Mary’s Wellness Ltd (“MW”) founded by Virginia Vidal, a cannabis beverage trailblazer and a global medical cannabis influencer with a current product line of 100% organic items focused on medicinal cannabis and has a total of 18 varieties of convenient on-the-go brews. Redfund equity upside: ability to acquire through warrants and note conversion a substantial equity position once licensing is approved.
Winterlife Inc. (“WL”) founded in 2013 in Seattle, Washington, with close to CDN$3 million in sales through 600 dispensaries, has just launched the WinterlifeCBD product line that is free of THC, is 100% organic, vegan and gluten free. Redfund equity upside: through the promissory note convertibility feature if exercised, has the ability to acquire 50% of Winterlife Inc.
RxMM Health Care a division of RxMM Health Capital involved in manufacturing of CBD over-the-counter medications, and Alzheimers Defense (AD) a proprietary, CBD infused “all natural” nutraceutical product. Refund upside: note collateralized by intellectual property assets third party valued at over USD$40 million.
The 2019 Vision
Redfund Capital’s opportunity in emerging markets and the unique market conditions in the cannabis industry make it possible for the Company to uniquely grow in the first quarter of 2019. Two of the companies in our present portfolio are already investigating the step by step process to file applications to the Canadian Securities Exchange and hope to become stand alone public companies in the first quarter. The ability to convert our notes and warrants into equity of these companies and the first right of refusal on all debt and equity will enable Redfund to continue to create a strong upside potential for our shareholders. Redfund will press information as it becomes publically available and as the Company converts its equity positions.
The Company is in the right space at the right time. Redfund has a clear value of what the Company brings to the market and to the Redfund shareholders. The ROI on any new emerging market, tends to be a year or more down the line. The opportunity to gain market share will never be greater than when a market is newly emerging and cannabis globalization is already here and will only expand in the coming year.
“The Company vision is to have a portfolio of 20 companies with $75 million injected through loans deployed to companies who have commonalities of revenues, brand awareness, and a keen interest to go global with their products. We know the opportunity operating as an international business and continuing to invest in that future concept is advantageous to our shareholders. The hot IPO scenario is actually still in its infancy for the medical cannabis industry as it mainstreams, and we are looking forward to our portfolio companies being leaders in the public markets,” stated Meris Kott, CEO.
About Redfund Capital Inc.
Redfund intends to provide debt and equity funding in the mid-to-late stages of a target company’s development or in technologies that are developed and validated by revenues. The present focus of the merchant bank is on medical cannabis, hemp and CBD-related and healthcare-related companies.
For further information please visit www.redfundcapital.com
For more information on Redfund Capital contact Meris Kott CEO 604.484.8989 or email@example.com
Further information about the Company is available on www.SEDAR.com under the Company’s profile.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the Property, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.